diquafosol has been researched along with Brain Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abraham, WM; Boucher, RC; Boyer, J; Cowlen, M; Davis, CW; Dougherty, R; Jones, AC; Lang-Furr, M; Picher, M; Sabater, JR; Stutts, MJ; Yerxa, BR | 1 |
1 other study(ies) available for diquafosol and Brain Neoplasms
| Article | Year |
|---|---|
Pharmacology of INS37217 [P(1)-(uridine 5')-P(4)- (2'-deoxycytidine 5')tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosis.
Topics: Animals; Astrocytoma; Brain Neoplasms; Calcium; Chlorides; Cilia; Cystic Fibrosis; Deoxycytosine Nucleotides; Epithelial Cells; Humans; In Situ Hybridization; In Vitro Techniques; Indicators and Reagents; Macaca mulatta; Mucins; Mucociliary Clearance; Ophthalmic Solutions; Polyphosphates; Purinergic P2 Receptor Agonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y2; Reverse Transcriptase Polymerase Chain Reaction; Sheep; Tumor Cells, Cultured; Uracil Nucleotides; Uridine | 2002 |